Addition of Lenalidomide to Azacitidine in Higher Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study. (April 2017) - Finelli, C.; Clissa, C.; Follo, M.; Barraco, M.; Mongiorgi, S.; Avanzini, P.; Bosi, C.; Castagnari, B.; Candoni, A.; Crugnola, M.; Giannini, M.B.; Gobbi, M.; et al.